Repligen (RGEN) - Cash on Hand

Cash on Hand as of September 2025 : €0.64 Billion

According to Repligen 's latest financial reports the company has €0.64 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Repligen - Cash on Hand chart (from 1996 to 2025)

Cash on Hand by year

Year	Cash on Hand	Change
2024-12-31	€0.72 B	7.08%
2023-12-31	€0.67 B	16.88%
2022-12-31	€0.58 B	9.06%
2021-12-31	€0.53 B	-8.57%
2020-12-31	€0.58 B	23.64%
2019-12-31	€0.47 B	178.4%
2018-12-31	€0.16 B	16.99%
2017-12-31	€0.14 B	7.44%
2016-12-31	€0.13 B	105.34%
2015-12-31	€65.64 M	36.58%
2014-12-31	€48.06 M	7.71%
2013-12-31	€44.62 M	47.36%
2012-12-31	€30.28 M
2011-03-31	€35.04 M	-10.4%
2010-03-31	€39.11 M	6%
2009-03-31	€36.9 M	17.09%
2008-03-31	€31.51 M	85.78%
2007-03-31	€16.96 M	7.67%
2006-03-31	€15.75 M	18.17%
2005-03-31	€13.33 M	18.13%
2004-03-31	€11.28 M	-21.3%
2003-03-31	€14.34 M	-39.94%
2002-03-31	€23.87 M	-12.62%
2001-03-31	€27.32 M	-23.15%
2000-03-31	€35.55 M	1063.91%
1999-03-31	€3.05 M	-22.86%
1998-03-31	€3.96 M	34.29%
1997-03-31	€2.94 M	-49.28%
1996-03-31	€5.81 M

Cash on Hand for similar companies or competitors

Company	Cash on Hand	differencediff.	Country
Novavax NVAX	€0.65 B	1.89%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	€1.26 B	97.38%	🇺🇸 USA
Neurocrine Biosciences NBIX	€0.95 B	48.89%	🇺🇸 USA
General Electric GE	€11.60 B	1,704.21%	🇺🇸 USA
Thermo Fisher Scientific TMO	€3.04 B	373.59%	🇺🇸 USA
Bristol-Myers Squibb BMY	€14.17 B	2,103.95%	🇺🇸 USA
Pfizer PFE	€12.86 B	1,901.21%	🇺🇸 USA
Bio-Techne TECH	€0.12 B	-80.64%	🇺🇸 USA
Sangamo Therapeutics SGMO	€25.43 M	-96.04%	🇺🇸 USA
Charles River Laboratories CRL	€0.17 B	-72.34%	🇺🇸 USA

Repligen (RGEN) - Cash on Hand

Cash on Hand as of September 2025 : €0.64 Billion

Repligen - Cash on Hand chart (from 1996 to 2025)

Cash on Hand by year

Cash on Hand for similar companies or competitors

What is the market capitalization of a company?

DISCLAIMER

Contact

Links